IntelliPharmaCeutics is actively seeking opportunities to license its proprietary drug delivery platforms to owners of patented, branded multiple dose per day products. The natural life cycle of those products can be extended far beyond the expiry of the underlying patents, when ordinarily generic introductions might be expected to cause substantial sales erosion. The development of a proprietary controlled release formulation, for sale under the banner of the original, established brand, is a sound brand management strategy which should be considered long before the expiry of the patents.

For more information contact Yogish Kamath, Director of New Business Development at ykamath@intellipharmaceutics.com